EAN 2026: Bocunebart’s promise as migraine preventive in treatment-refractory patients - Pharmaceutical Technology

Bocunebart's PACAP-targeting mechanism positions it as a potential first-in-class therapy in a thin pipeline of novel late-stage candidates Bocunebart's PACAP-targeting mechanism positions it as a potential first-in-class therapy in a thin pipeline of novel late-stage candidates. The current preventive landscape in migraine is highly competitive, especially since the launch of the calcitonin gene related peptide (CGRP)-targeting therapies, first with the mAbs and then the gepants. Image credit: [Tunatura]/Shutterstock.com On 29 June, at the 12 th Congress of the European Academy of Neurology (EAN) 2026, as part of a late-breaking e-poster session, Phase II program outcomes were presented for Lundbeck’s anti-pituitary…

GlobalData Healthcare · 2026-07-01

Bocunebart's PACAP-targeting mechanism positions it as a potential first-in-class therapy in a thin pipeline of novel late-stage candidates

Source: Pharmaceutical Technology